Glycooptimized TrastuzuMab-GEX (TrasGEX / GT-Mab 7.3-GEX)

TrasGEX is an improved version of the marketed blockbuster drug Trastuzumab / Herceptin (Roche, Genentech, Chugaj). Trastuzumab is targeting the HER2-receptor, commonly overexpressed in a variety of cancers.

Herceptin has been approved for the treatment of HER2 positive breast cancer and HER2 positive stomach cancer.

Glycotope´s TrasGEX has been glycooptimized in Glycotope´s fully human development platform GlycoExpressTM. As a result, TrasGEX shows a significantly improved ADCC-activity, in particular among all allotypes of the FcγIIIa-receptor mediating the ADCC, promising a significantly better therapeutic outcome for all patients eligible for treatment with Trastuzumab. Simultaneously, the fully human nature of Tras-GEX’ host cell lines avoids the common immunogenic reactions against host-derived non-human components.

TrasGEX Phase II is estimated to start in Q3 / 2013.